Highly potent HCV NS4B inhibitors with activity against multiple genotypes

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 2161-2166

  Phillips, Barton ^a   Cai, Ruby ^a   Delaney, William ^a   Du, Zhimin ^a   Ji, Mingzhe ^a   Jin, Haolun ^a   Lee, Johnny ^a   Li, Jiayao ^a   Niedziela Majka, Anita ^a   Mish, Michael ^a   Pyun, Hyung Jung ^a   Saugier, Joe ^a,b   Tirunagari, Neeraj ^a   Wang, Jianhong ^a   Yang, Huiling ^a   Wu, Qiaoyin ^a   Sheng, Chris ^a,c   Zonte, Catalin ^a  

^a GILEAD SCIENCES   (United States)

^b Accelas Pharmaceutical Inc Xianlin University City ^*  (United States)

^c Nanjing Institute of Industry Technology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXADIAZOLOQUINOLINE; ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 4B INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; RAT;

GENOTYPE; HEPACIVIRUS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896300974     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401646w     Document Type: Article

References (13)

1. Armstrong, G. L.; Wasley, A.; Simard, E. P.; McQuillan, G. M.; Kuhnert, W. L.; Alter, M. J. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 Ann. Intern. Med. 2006, 144, 705-714
2. Poordad, F.; Dieterich, D. Treating Hepatitis C: Current Standard of Care and Emerging Direct-Acting Antiviral Agents J. Viral Hepatitis 2012, 19, 449-464
3. Nguyene, M. H.; Keeffe, E. B. Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6 Clin. Gastroenterol. Hepatol. 2005, 3, S97-S101
4. Nyanguile, O.; Devogelaer, B.; Vijgen, L.; Van den Broeck, W.; Pauwels, F.; Cummings, M. D.; De Bondt, H. L.; An Vos, A. M.; Berke, J. M.; Lenz, O.; Vandercruyssen, G.; Vermeiren, K.; Mostmans, W.; Dehertogh, P.; Delouvroy, F.; Vendeville, S.; VanDyck, K.; Dockx, K.; Cleiren, E.; Raboisson, P.; Simmen, K. A.; Fanning, G. C. 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus J. Virol. 2011, 84, 2923-2934
5. Halfoni, H. L.; Locarnini, S. Hepatitis C Virus Resistance to Protease Inhibitors J. Hepatol. 2011, 55, 192-206
6. Melnikova, I. Hepatitis C-Pipeline Update Nat. Rev. Drug Discovery 2011, 10, 93-94
7. Li, S.; Yu, X.; Guo, Y.; Kong, L. Interaction Networks of Hepatitis C Virus NS4B: Implications for Antiviral Therapy Cell. Microbiol. 2012, 14, 994-1002
8. Shotwell, J. B.; Baskaran, S.; Chong, P.; Creech, K. L.; Crosby, R. M.; Dickson, H.; Fang, J.; Garrido, D.; Mathis, A.; Maung, J.; Parks, D. J.; Pouliot, J. J.; Price, D. J.; Rai, R.; Seal, J. W., III; Schmitz, U.; Tai, V. W. F.; Thomson, M.; Xie, M.; Xiong, Z. Z.; Peat, A. J. Imidazo[1,2- a ]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization ACS Med. Chem. Lett. 2012, 3, 565-569
9. Roberts, S. D.; Peat, A. J. HCV Replication Inhibitors That Interact with NS4B. In Successful Strategies for the Discovery of Antiviral Drugs; Desai, M. C.; Meanwell, N. A., Eds.; Royal Society of Chemistry: Cambridge, U.K., 2013; pp 110-145.
10. Miller, J. F.; Chong, P. Y.; Shotwell, J. B.; Catalano, J. G.; Tai, V. W. F.; Fang, J.; Banka, A. L.; Roberts, C. D.; Youngman, M.; Zhang, H.; Xiong, Z.; Mathis, A.; Pouliot, J. J.; Hamatake, R. K.; Price, D. J.; Seal, J. W.; Stroup, L. L.; Creech, K. L.; Carballo, L. H.; Todd, D.; Spaltenstein, A.; Furst, S.; Hong, Z.; Peat, A. J. Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein. J. Med. Chem. [Online early access]. DOI: 10.1021/ jm400125h. Published Online: Apr 1, 2013.
11. Zhang, X.; Zhang, N.; Chen, G.; Turpoff, A.; Ren, H.; Takasugi, J.; Morrill, C.; Zhu, J.; Li, C.; Lennox, W.; Paget, S.; Liu, Y.; Almstead, N.; Njoroge, F.; Gu, Z.; Komatsu, T.; Clausen, V.; Espiritu, C.; Graci, J.; Colacino, J.; Lahser, F.; Risher, N.; Weetall, M.; Nomeir, A.; Karp, G. M. Bioorg. Med. Chem. Lett. 2013, 23, 3947-3953
12. Zhang, N.; Zhang, X.; Zhu, J.; Turpoff, A.; Chen, G.; Morrill, C.; Huang, S.; Lennox, W.; Kakarla, R.; Liu, R.; Li, C.; Ren, H.; Almstead, N.; Venkatraman, S.; Njoroge, F. G.; Gu, Z.; Clausen, V.; Graci, J.; Jung, S. P.; Zheng, Y.; Colacino, J. M.; Lahser, F.; Sheedy, J.; Mollin, A.; Weetall, M.; Nomeir, A.; Karp, G. M.. Structure-Activity Relationship (SAR) Optimization of 6-(Indol-2-yl)pyridine-3-sulfonamides: Identification of Potent, Selective, and Orally Bioavailable Small Molecules Targeting Hepatitis C (HCV) NS4B. J. Med. Chem. [Online early access]. DOI: 10.1021/jm401621g. Published Online: Nov 22, 2013.
13. Kakarla, R.; Liu, J.; Naduthambi, D.; Chang, W.; Mosley, R. T.; Bao, D.; Steuer, H. M. M.; Keilman, M.; Bansal, S.; Lam, A. M.; Seibel, W.; Neilson, S.; Furman, P. A.; Sofia, M. J. Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives. J. Med. Chem. [Online early access]. DOI: 10.1021/jm4012643. Published Online: January 29, 2014.